Cargando…

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of cort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milara, Javier, Morell, Anselm, Ballester, Bea, Sanz, Celia, Freire, Jose, Qian, Xiaozhong, Alonso-Garcia, Maggie, Morcillo, Esteban, Cortijo, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335416/ https://www.ncbi.nlm.nih.gov/pubmed/25652132 http://dx.doi.org/10.1186/s12931-015-0179-5

Ejemplares similares

Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model
por: Milara, Javier, et al.
Publicado: (2015)

Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients
por: Milara, Javier, et al.
Publicado: (2016)

Evaluation of Mucociliary Clearance by Three Dimension Micro-CT-SPECT in Guinea Pig: Role of Bitter Taste Agonists
por: Ortiz, Jose Luis, et al.
Publicado: (2016)

MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease
por: Milara, Javier, et al.
Publicado: (2018)

The JAK2 pathway is activated in idiopathic pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2018)

Roflumilast Inhibits Respiratory Syncytial Virus Infection in Human Differentiated Bronchial Epithelial Cells
por: Mata, Manuel, et al.
Publicado: (2013)

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients
por: Milara, Javier, et al.
Publicado: (2019)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Obacunone Photoprotective Effects against Solar-Simulated Radiation–Induced Molecular Modifications in Primary Keratinocytes and Full-Thickness Human Skin
por: Montero, Paula, et al.
Publicado: (2023)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination: RE(2)SPOND rationale and study design
por: Rennard, Stephen I, et al.
Publicado: (2016)

Nitric Oxide System and Bronchial Epithelium: More Than a Barrier
por: Bayarri, María Amparo, et al.
Publicado: (2021)

New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

Does roflumilast induce phagocytic activity in COPD patients?
por: Ghosh, Baishakhi, et al.
Publicado: (2015)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast
por: Barnes, Neil C, et al.
Publicado: (2014)

The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro
por: Milara, Javier, et al.
Publicado: (2022)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
por: Ballester, Beatriz, et al.
Publicado: (2019)

Mucins as a New Frontier in Pulmonary Fibrosis
por: Ballester, Beatriz, et al.
Publicado: (2019)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

The role of mucin 1 in respiratory diseases
por: Ballester, Beatriz, et al.
Publicado: (2021)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway
por: Ballester, Beatriz, et al.
Publicado: (2021)

Aclidinium inhibits human lung fibroblast to myofibroblast transition
por: Milara, Javier, et al.
Publicado: (2011)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD
por: Reddy, Aravind T, et al.
Publicado: (2020)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
por: Puhan, Milo A., et al.
Publicado: (2015)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis
por: Yuan, Lianfang, et al.
Publicado: (2016)

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
por: Watz, Henrik, et al.
Publicado: (2018)

A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers
por: Matencio, Adrián, et al.
Publicado: (2019)

The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020)

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_59vusl64sm0godi39dtb1p400j